Avidity Biosciences Inc
RNAM
Peringkat dalam Saham
#2068
Avidity Biosciences, Inc. is at the forefront of developing a novel class of... Avidity Biosciences, Inc. is at the forefront of developing a novel class of oligonucleotide-based therapies, known as Antibody Oligonucleotide Conjugates (AOCs). Utilizing its proprietary AOC platform, the company engineers treatments that strategically merge the targeted delivery capabilities of monoclonal antibodies with the precise action of oligonucleotide-based therapeutics. This innovative method aims to reach cell and tissue types previously inaccessible to treatment, thereby more effectively addressing the fundamental genetic causes of various diseases. The company was established on November 13, 2012, by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, and its main office is located in San Diego, California.
Harga Saham
$71.34
Terakhir disinkronkan: 2026-03-03
Kapitalisasi Pasar
$9.84B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-
Negara
US
Perdagangan Avidity Biosciences Inc (RNAM)
Kategori
Healthcare
Rasio P/B untuk Avidity Biosciences Inc (RNAM)
Rasio P/B per October 2026 TTM: 6.44
Menurut laporan keuangan dan harga saham terbaru dari Avidity Biosciences Inc, rasio P/B saat ini (TTM) adalah 6.44. Pada akhir 2024, rasio P/B perusahaan adalah 5.69.
Riwayat rasio P/B untuk Avidity Biosciences Inc dari 2018 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 6.44 | 8.80% |
| 2025 | 5.92 | 4.15% |
| 2024 | 5.69 | -46.29% |
| 2023 | 10.59 | 61.58% |
| 2022 | 6.55 | -16.92% |
| 2021 | 7.89 | 53.53% |
| 2020 | 5.14 | -112.32% |
| 2019 | -41.71 | -37.04% |
| 2018 | -66.25 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| 6.251 | -2.95% |
US
|
|
| 13.6307 | 111.63% |
US
|
|
| 4.4521 | -30.88% |
AU
|
|
| 3.2932 | -48.87% |
BE
|
|
| 6.3632 | -1.21% |
NL
|
